Genetic elimination of α3(IV) collagen fails to rescue anti-collagen B cells

Immunology Letters

Volumn 141, Issue 1, 2011, Pages 134-139

  Clark, Amy G ^a,b   Mackin, Katherine M ^a,b   Foster, Mary H ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

Author keywords

Alpha3(IV) collagen; Anti glomerular basement membrane; B cell; Goodpasture; Tolerance

Indexed keywords

AUTOANTIBODY; COLLAGEN ANTIBODY; COLLAGEN TYPE 4; COLLAGEN TYPE IV ALPHA3 CHAIN; IMMUNOGLOBULIN D ANTIBODY; IMMUNOGLOBULIN LAMBDA CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; IMMUNOGLOBULIN M ANTIBODY; UNCLASSIFIED DRUG;

ALLOTYPE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY DETECTION; ARTICLE; B LYMPHOCYTE; CELL FATE; COLLAGEN DEFECT; CONTROLLED STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENIC MOUSE;

ANIMALS; ANTI-GLOMERULAR BASEMENT MEMBRANE DISEASE; AUTOANTIBODIES; AUTOANTIGENS; B-LYMPHOCYTES; CLONAL DELETION; COLLAGEN TYPE IV; DISEASE MODELS, ANIMAL; EPITOPES; EXTRACELLULAR MATRIX; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; MODELS, ANIMAL; SELF TOLERANCE;

EID: 80955148920     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2011.09.004     Document Type: Article

References (38)

1. Gammon W.R., Briggaman R.A. Epidermolysis bullosa acquisita and bullous systemic lupus erythematosus. Diseases of autoimmunity to type VII collagen. Dermatol Clin 1993, 11:535-547.
2. Ghohestani R., Hudson B., Claudy A., Uitto J. The α5 chain of type IV collagen is the target of IgG autoantibodies in a novel autoimmune disease with subepidermal blisters and renal insufficiency. J Biol Chem 2000, 275:16002-16006.
3. Haque M.A., Mizobuchi T., Yasufuku K., Fujisawa T., Brutkiewicz R.R., Zheng Y., et al. Evidence for immune responses to a self-antigen in lung transplantation: role of type V collagen-specific T cells in the pathogenesis of lung allograft rejection. J Immunol 2002, 169:1542-1549.
4. Luross J.A., Williams N.A. The genetic and immunopathological processes underlying collagen-induced arthritis. Immunology 2001, 103:407-416.
5. Xu L., Robinson N., Miller S.D., Chan L.S. Characterization of BALB/c mice B lymphocyte autoimmune responses to skin basement membrane component type XVII collagen, the target antigen of autoimmune skin disease bullous pemphigoid. Immunol Lett 2001, 77:105-111.
6. Morgan K. What do anti-collagen antibodies mean?. Ann Rheum Dis 1990, 49:62-65.
7. Hudson B.G., Tryggvason K., Sundaramoorthy M., Neilson E.G. Alport's syndrome, Goodpasture's syndrome, and type IV collagen. N Engl J Med 2003, 348:2543-2556.
8. Hudson B.G., Reeders S.T., Tryggvason K. Type IV collagen: structure, gene organization, and role in human diseases. Molecular basis of Goodpasture and Alport syndromes and diffuse leiomyomatosis. J Biol Chem 1993, 268:26033-26036.
9. Lerner R.A., Glassock R.J., Dixon F.J. The role of anti-glomerular basement membrane antibody in the pathogenesis of human glomerulonephritis. J Exp Med 1967, 126:989-1004.
10. Ryan J.J., Mason P.J., Pusey C.D., Turner N. Recombinant alpha-chains of type IV collagen demonstrate that the amino terminal of the Goodpasture autoantigen is crucial for antibody recognition. Clin Exp Immunol 1998, 113:17-27.
11. Hellmark T., Segelmark M., Unger C., Burkhardt H., Saus J., Wieslander J. Identification of a clinically relevant immunodominant region of collagen IV in Goodpasture disease. Kidney Int 1999, 55:936-944.
12. Netzer K.O., Leinonen A., Boutaud A., Borza D.B., Todd P., Gunwar S., et al. The Goodpasture autoantigen. Mapping the major conformational epitope(s) of α3(IV) collagen to residues 17-31 and 127-141 of the NC1 domain. J Biol Chem 1999, 274:11267-11274.
13. Borza D., Bondar O., Todd P., Sundaramoorthy M., Sado Y., Ninomiya Y., et al. Quaternary organization of the Goodpasture autoantigen, the α 3(IV) collagen chain. Sequestration of two cryptic autoepitopes by intrapromoter interactions with the α4 and α5 NC1 domains. J Biol Chem 2002, 277:40075-40083.
14. Vanacore R.M., Ham A.J., Cartailler J.P., Sundaramoorthy M., Todd P., Pedchenko V., et al. A role for collagen IV cross-links in conferring immune privilege to the Goodpasture autoantigen: structural basis for the crypticity of B cell epitopes. J Biol Chem 2008, 283:22737-22748.
15. Zhang Y., Su S.C., Hecox D.B., Brady G.F., Mackin K.M., Clark A.G., et al. Central tolerance regulates B cells reactive with Goodpasture antigen α3(IV)NC1 collagen. J Immunol 2008, 181:6092-6100.
16. Wieczorek G., Steinhoff C., Schulz R., Scheller M., Vingron M., Ropers H.H., et al. Gene expression profile of mouse bone marrow stromal cells determined by cDNA microarray analysis. Cell Tissue Res 2003, 311:227-237.
17. Hamano Y., Zeisberg M., Sugimoto H., Lively J.C., Maeshima Y., Yang C., et al. Physiological levels of tumstatin, a fragment of collagen IV α3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via αV β3 integrin. Cancer Cell 2003, 3:589-601.
18. Miner J.H., Sanes J.R. Molecular and functional defects in kidneys of mice lacking collagen α3(IV): implications for Alport syndrome. J Cell Biol 1996, 135:1403-1413.
19. Sackey F.N., Congdon K.L., Brady G.F., Hopfer H., Zhang Y., Mackin K.M., et al. Shared variable domain elements among anti-collagen antibodies reactive with Goodpasture epitopes. Autoimmunity: role, regulation and disorder 2008, Nova Science Publishers, Inc., Hauppauge, NY. F.L. Vogel, L.F. Zimmermann (Eds.).
20. Andrews K.L., Mudd J.L., Li C., Miner J.H. Quantitative trait loci influence renal disease progression in a mouse model of Alport syndrome. Am J Pathol 2002, 160:721-730.
21. Spanopoulou E., Roman C.A.J., Corcoran L.M., Schlissel M.S., Silver D.P., Nemazee D., et al. Functional immunoglobulin transgenes guide ordered B-cell differentiation in Rag-1-deficient mice. Genes Dev 1994, 8:1030-1042.
22. Kramer A., Keitel T., Winkler K., Stocklein W., Hohne W., Schneider-Mergener J. Molecular basis for the binding promiscuity of an anti-p24 (HIV-1) monoclonal antibody. Cell 1997, 91:799-809.
23. DeLano W.L., Ultsch M.H., de Vos A.M., Wells J.A. Convergent solutions to binding at a protein-protein interface. Science 2000, 287:1279-1283.
24. James L.C., Roversi P., Tawfik D.S. Antibody multispecificity mediated by conformational diversity. Science 2003, 299:1362-1367.
25. Bostrom J., Yu S.F., Kan D., Appleton B.A., Lee C.V., Billeci K., et al. Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Science 2009, 323:1610-1614.
26. Stefferl A., Schubart A., Storch M., Amini A., Mather I., Lassmann H., et al. Butyrophilin, a milk protein, modulates the encephalitogenic T cell response to myelin oligodendrocyte glycoprotein in experimental autoimmune encephalomyelitis. J Immunol 2000, 165:2859-2865.
27. Wong D., Phelps R.G., Turner A.N. The Goodpasture antigen is expressed in the human thymus. Kidney Int 2001, 60:1777-1783.
28. Derry C.J., Ross C.N., Lombardi G., Mason P.D., Rees A.J., Lechler R.I., et al. Analysis of T-cell responses to the autoantigen in Goodpasture's disease. Clin Exp Immunol 1995, 100:262-268.
29. Merkel F., Kalluri R., Marx M., Enders U., Stevanovic S., Giegerich G., et al. Autoreactive T-cells in Goodpasture's syndrome recognize the N-terminal NCI domain on α3 type 1V collagen. Kidney Int 1996, 49:1127-1133.
30. Zou J., Hannier S., Cairns L.S., Barker R.N., Rees A.J., Turner A.N., et al. Healthy individuals have Goodpasture autoantigen-reactive T cells. J Am Soc Nephrol 2008, 19:396-404.
31. Bolton W.K., Tucker F.L., Sturgill B.C. New avian model of experimental glomerulonephritis consistent with mediation by cellular immunity. J Clin Invest 1984, 73:1263-1276.
32. Bolton W.K., Chen L., Hellmark T., Wieslander J., Fox J.W. Epitope spreading and autoimmune glomerulonephritis in rats induced by a T cell epitope of Goodpasture's antigen. J Am Soc Nephrol 2005, 16:2657-2666.
33. Arends J., Wu J., Borillo J., Troung L., Zhou C., Vigneswaran N., et al. T cell epitope mimicry in antiglomerular basement membrane disease. J Immunol 2006, 176:1252-1258.
34. Shah M.K., Hugghins S.Y. Characteristics and outcomes of patients with Goodpasture's syndrome. South Med J 2002, 95:1411-1418.
35. Hellmark T., Johansson C., Wieslander J. Characterization of anti-GBM antibodies involved in Goodpasture's syndrome. Kidney Int 1994, 46:823-829.
36. Borza D.B., Netzer K.O., Leinonen A., Todd P., Cervera J., Saus J., et al. The Goodpasture autoantigen. Identification of multiple cryptic epitopes on the NC1 domain of the alpha3(IV) collagen chain. J Biol Chem 2000, 275:6030-6037.
37. Pedchenko V., Bondar O., Fogo A., Vanacore R., Voziyan P., Kitching A.R., et al. Molecular architecture of the Goodpasture autoantigen in anti-GBM nephritis. N Engl J Med 2010, 363:343-354.
38. Chen L., Hellmark T., Wieslander J., Bolton W.K. Immunodominant epitopes of alpha3(IV)NC1 induce autoimmune glomerulonephritis in rats. Kidney Int 2003, 64:2108-2120.